Rapid Response to Certolizumab Pegol in Hidradenitis Suppurativa: A Case Report

Conclusion: Certolizumab pegol is a humanized antigen-binding fragment of a monoclonal antibody which binds to TNF-alpha. However, certolizumab pegol is only approved for plaque psoriasis in dermatology; it is likely to be a promising effective agent for HS, especially in challenging cases.Skin Appendage Disord
Source: Skin Appendage Disorders - Category: Dermatology Source Type: research